Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2B double-blind, randomized, placebo-controlled, multisite dose-ranging study to assess the efficacy, safety, pharmacokinetics and the optimal dose of bumetanide in children and adolescents with autism spectrum disorder.

Next Previous
X
Search
Trial Profile

A Phase 2B double-blind, randomized, placebo-controlled, multisite dose-ranging study to assess the efficacy, safety, pharmacokinetics and the optimal dose of bumetanide in children and adolescents with autism spectrum disorder.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bumetanide (Primary)
  • Indications Pervasive child development disorders
  • Focus Therapeutic Use
  • Sponsors Neurochlore

    • Most Recent Events

    • 05 Oct 2021 Results investigating the ability of CARS to detect changes by comparing its changes with those of the Clinical Global Impression Scale-Improvement, presented at the 34th Annual Congress of the European College of Neuropsychopharmacology
    • 22 Mar 2017 New trial record
    • 14 Mar 2017 Results published in the Translational Psychiatry.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top